Financial disclosures

Size: px
Start display at page:

Download "Financial disclosures"

Transcription

1 An update on immunohistochemical markers in mesenchymal neoplasms By Konstantinos Linos MD, FCAP, FASDP Assistant Professor of Pathology Geisel School of Medicine at Dartmouth Dartmouth-Hitchcock Medical Center Lebanon, NH, USA Financial disclosures Book Royalties A general truth! Some of these markers may prove to be more useful in clinical practice than others With time it is generally appreciated that significant overlap in staining patterns can be seen in different tumor types, some of which share similar biology or can be explained by known biologic mechanisms 1

2 Outline ERG PAX7 DUX4/ETV4 BCOR Claudin 4 STAT6 MUC4 ERG Member of the ETS family of regulatory transcription factors with diverse biological roles Regulates endothelial cell differentiation, angiogenesis, and expression of several endothelial-specific antigens Also required for embryonic stem cells to differentiate into endothelial cells Regulatory gene of cartilage skeletogenesis May have crucial role in permanent cartilage develpment 2

3 ERG in benign vascular tumors ERG in Hemangioendotheliomas 3

4 ERG in angiosarcoma in comparison with CD31 ERG in non epithelial Mesenchymal, Neuroectodermal and Hematopoietic tumors ERG in Epithelial Neoplams 4

5 ERG in nonvascular tumors A hemorrhagic poorly differentiated carcinoma simulating angiosarcoma 5

6 ERG From these studies ERG is positive in >95% of angiosarcomas, with a greater sensitivity compared to CD31 and CD34 ERG usually shows a diffuse pattern of nuclear staining, which facilitates its interpretation in this context. 6

7 Ewing Sarcoma with EWSR1- ERG FLI1 ERG 7

8 Ewing sarcoma with EWSR1-FLI1 EWSR1, FLI1, ERG and their fusion proteins in Ewing Sarcoma 8

9 Leukemia cutis cases Reactive Leukocytic Infiltrates 9

10 10

11 Soft Tissue Chondroma Convetional Chondrosarcoma ERG 11

12 FLI1 ERG Conclusion ERG is therefore a useful marker for confirming endothelial differentiation in both benign and malignant neoplasms Potentially useful marker to distinguish Leukemia Cutis vs reactive myeloid infiltrates Expression can also be seen in a subset of epithelioid sarcomas and a small percentage of Ewing sarcomas, as well as approximately 45% to 50% of prostatic carcinomas. ERG can be seen in selected bone and soft tissue tumor with cartilaginous differentiation Outline ERG PAX7 DUX4-ETV4 BCOR Claudin 4 STAT6 MUC4 12

13 PAX7 Immunohistochemical detection in tumor cell nuclei of myogenin and MYOD1 currently benchmark for rhabdomyosarcoma diagnosis Sensitivity and specificity even in combination is imperfect Negative or focal myogenin in a considerable number of embryonal rhabdomyosarcomas MYOD1: high background and cytoplasmic staining PAX7 PAX7 is a paired box transcription factor required for mammalian skeletal muscle stem cells (aka satellite cells) It plays a critical role in mammalian myogenesis Controls early lineage specification, whereas MYOG and MYOD1 regulate subsequent lineage commitment 13

14 Embryonal Rhabdomyosarcoma 14

15 Embryonal Rhabdomyosarcoma Alveolar Rhabdomyosarcoma 15

16 PAX7 and Rhabdomyosarcoma Potential diagnostic value of PAX7 IHC in the evaluation of rhabdomyosarcoma, especially embryonal rhabdomyosarcoma Less sensitive in ARMS Could be used secondarily in desmin+, MYOG/MYOD1 - cases 16

17 Ewing Sarcoma CIC-DUX4 PAX7 a sensitive marker for Ewing Sarcoma Positive in NKX2-2 negative cases Also positive in both common and variant forms of Ewing Sarcoma PAX7 expression differentiates Ewing Sarcoma from CIC-DUX4 sarcoma What accounts for the robust PAX7 expression in Ewing Sarcoma? EWSR1-FLI fusion protein binds at position 5 to the PAX7 promoter 17

18 Undifferentiated small round cell or spindle-cell tumor PAX7 positivity: Rhabdo vs Ewing Sarcoma Positivity for desmin, MYOG, MYOD1 would strongly favor rhabdomyosarcoma Rare cases of ES can express myogenic features Diffuse membranous CD99 would favor ES Can be positive in rhabdomyosarcomas NKX2.2 would support ES WT1+, PAX7- would support CIC-DUX4 To date IHC focused on the aberrant expression of one of the genes involved in the pathogenic translocation WT1 in DSMRCT (EWSR1-WT1) STAT6 in SFT (NAB2-STAT6) FLI1 in Ewing Sarcoma (ESWR1-FLI1) BCOR in undifferentiated sarcomas PAX7 in ES exploits a characteristic transcriptional read-out of the diseasecausing translocation 18

19 Outline ERG PAX7 DUX4 & ETV4 BCOR Claudin 4 STAT6 MUC4 DUX4 IHC Emerging undifferentiated sarcomas resembling but distinct from Ewing Sarcoma t(4;19) translocation involving CIC-DUX4 t(10;19) translocation CIC-DUX4L Distinct transcriptional signature with poor clinical outcomes 19

20 CD99 WT1 FISH CIC Ewing Sarcoma Malignant Rhabdoid Synovial Sarcoma Tumor 20

21 21

22 ETV4 (ETS Variant 4) Member of the PEA3 subgroup in the ETS transcription factor family Upregulation of WT1 and ETV1/4/5 in CICrearranged sarcomas 22

23 23

24 ETV4 and round cell sarcomas Sensitive but not entirely specific for CICrearranged sarcomas Diffuse, moderate-to-strong expression in ~90% sensitive and 95% specific Outline ERG PAX7 DUX4 & ETV4 BCOR Claudin 4 STAT6 MUC4 24

25 BCOR (BCL-6 interacting corepressor) A subset of undifferentiated round cell sarcomas: BCOR-CCNB3 BCOR-MAML3 ZC3H7B-BCOR YWHAE-NUTM2B BCOR internal tandem duplication (ITD) Clear cell sarcoma of the kidney Primitive myxoid mesenchymal tumor of infancy 25

26 BCOR and Synovial Sarcoma 26

27 27

28 BCOR BCOR IHC is highly sensitive in identifying sarcomas with BCOR abnormality Triage for further molecular tests Avoid extensive IHC and molecular workups in small specimens Synovial sarcoma should be included in the DDx of round cell sarcomas with BCOR+ 28

29 Outline ERG PAX7 DUX4 & ETV4 BCOR Claudin 4 STAT6 MUC4 Claudin 4 and SWI/SNF complex-deficient tumors Claudins are integral components of tight junctions which for barriers in epithelial, endothelial and perineurial cells Claudin 4 is expressed in most epithelial cells and carcinomas Has been validated as a useful marker in the distinction of mesothelioma (lack of expression) from metastatic adenocarcinoma (consistently +) Claudin 4 It has been observed: Epithelial component of biphasic synovial sarcoma Subset of Desmoplastic Small Round Cell Tumor 29

30 SWI/SNF complex Fundamental role in regulation of gene expression Tumor suppressor properties SMARCB1 (INI-1) SMARCA2 (BRM) SMARCA4 (BRG1) ARID1A SWI/SNF complex SMARCB1 deficiency (INI1 loss) Malignant Rhabdoid Tumor Epithelioid Sarcoma Subset of myoepithelial carcinomas Epithelioid MPNST SMARCA4 deficiency (BRG1 loss) Nearly all cases of ovarian small cell carcinomas of hypercalcemic type ARID1A deficiency ~half of ovarian clear cell carcinomas 30

31 Epithelioid Sarcoma Epithelioid Angiosarcoma Epithelioid MPNST Biphasic Synovial Sarcoma 31

32 Ovarian Clear Cell Carcinoma Pancreatic Rhabdoid Carcinoma Cecal Rhabdoid Carcinoma INI1- deficient Sinonasal Carcinoma Claudin 4 It may serve as a useful diagnostic adjunct in the distinction of SWI/SNF complex deficient carcinomas from sarcomas with epithelioid morphology Strongly associated with true epithelial differentiation However absence of claudin 4 staining does not entirely exclude carcinoma 32

33 Keratin CD34 SMARCA4 33

34 Outline ERG PAX7 DUX4 & ETV4 BCOR Claudin 4 STAT6 MUC4 STAT6 and Solitaty Fibrous Tumor STAT6 is a member of the STAT family of cytoplasmic transcription factors, which regulate gene expression by transmitting signals to the nucleus and binding to specific DNA promoter sequences NAB2 is a transcriptional corepressor, a regulator of the early growth response 1 (EGR1) transcription factor 34

35 Variable truncation of the repressor domain of NAB2 with replacement by the transcriptional activation domain of STAT6 Subsequent translocation to the nucleus, where it acts as a transcriptional activator resulting in increased proliferation 35

36 Synovial sarcoma STAT6 Cellular spindle cell lipoma STAT6 36

37 Dedifferentiated liposarcoma Pitfall! Presence of STAT6 expression in approximately 7% to 15% of dedifferentiated liposarcomas The staining pattern in dedifferentiated liposarcoma is variable and may be focal or diffuse, weak or medium to strong in intensity, unlike the generally strong diffuse pattern seen in solitary fibrous tumor 37

38 Unlike the predominantly nuclear pattern of staining seen in solitary fibrous tumor, both cytoplasmic and nuclear expression is common in dedifferentiated liposarcoma. Diffuse expression of MDM2 and CDK4 helps favor a diagnosis of dedifferentiated liposarcoma If doubt persists, FISH for MDM2 amplification may also be useful FISH vs PCR Because STAT6 and NAB2 are located close together on the long arm of chromosome 12, FISH to demonstrate rearrangement of the genes is technically challenging and not diagnostically useful Outline ERG PAX7 DUX4 & ETV4 BCOR Claudin 4 STAT6 MUC4 38

39 MUC4 MUC4 is a useful marker for low-grade fibromyxoid sarcoma (LGFMS) and sclerosing epithelioid fibrosarcoma 39

40 Sclerosing epithelioid sarcoma 40

41 Monophasic synovial sarcoma and MUC4 Sclerosing epithelioid sarcoma, MUC4 and carcinoma Importantly, regarding SEF, in which a poorly differentiated carcinoma may fall into the differential diagnosis it should be remembered that MUC4 expression is seen in a variety of different carcinomas, such as pancreaticobiliary carcinomas, breast carcinoma, and colonic adenocarcinoma. NEVER FORGET! The use of all of these markers requires careful clinical correlation and knowledge of the spectrum of staining in other tumor types, as no one marker is 100% sensitive or specific for a given diagnosis 41

42 KonstantinosLin 42

Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement

Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center

More information

Financial disclosures

Financial disclosures Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchc Geisel School of

More information

Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction

Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques

More information

Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction

Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques

More information

Disclosure of Relevant Financial Relationships

Disclosure of Relevant Financial Relationships Ewing and Ewing like sarcomas Using Genetic Signatures in Refining Small Blue Round Cell Tumor Classification Cristina Antonescu, MD Department of Pathology Disclosure of Relevant Financial Relationships

More information

Surgical Pathology Evening Specialty Conference USCAP 2015

Surgical Pathology Evening Specialty Conference USCAP 2015 Surgical Pathology Evening Specialty Conference USCAP 2015 John R. Goldblum, M.D. Chairman, Department of Pathology, Cleveland Clinic Professor of Pathology, Cleveland Clinic Lerner College of Medicine

More information

Clinical History. Pediatric Tumors with Involvement of the Head & Neck

Clinical History. Pediatric Tumors with Involvement of the Head & Neck Pediatric Tumors with Involvement of the Head & Neck John Hicks Texas Children s Hospital Baylor College of Medicine Houston, TX NO DISCLOSURES Clinical History 10 Yr-Old Hispanic Male From Mexico with

More information

Enterprise Interest Nothing to declare

Enterprise Interest Nothing to declare Enterprise Interest Nothing to declare Diagnoses one would not like to miss in soft tissue pathology early in your career Marta Sbaraglia, MD Department of Pathology Hospital of Treviso University of Padua

More information

The last 10 years have seen the description of many

The last 10 years have seen the description of many An Update on the Application of Newly Described Immunohistochemical Markers in Soft Tissue Pathology George Lin, MD, PhD; Leona A. Doyle, MD Context. During the last 5 to 10 years, significant progress

More information

Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia

Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia Sílvia Bagué Servei de Patologia Hospital de Sant Pau Barcelona Soft tissue sarcomas Heterogeneous group

More information

Molecular pathology in soft tissue tumors. Sylvia Höller Pathologie

Molecular pathology in soft tissue tumors. Sylvia Höller Pathologie Molecular pathology in soft tissue tumors Sylvia Höller Pathologie When do we perform molecular testing? Morphology and IHC are not clearly fitting with an entity some translocations are entity specific

More information

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD Immunohistochemistry in Bone and Soft Tissue Tumors Sahar Rassi Zankoul, MD Introduction Bone tumors represent a wide variety of tumors of various origins and malignant potentials. These different tumor

More information

Molecular Diagnosis of Soft Tissue Tumors: Avoid Pitfalls

Molecular Diagnosis of Soft Tissue Tumors: Avoid Pitfalls Molecular Diagnosis of Soft Tissue Tumors: Avoid Pitfalls Cristina Antonescu, MD Department of Pathology Memorial Sloan-Kettering Cancer Center, New York Overview I. When should we rely on the help of

More information

Klinisch belang van chromosomale translocatie detectie in sarcomen

Klinisch belang van chromosomale translocatie detectie in sarcomen Translocations in sarcomas Klinisch belang van chromosomale translocatie detectie in sarcomen Judith V.M.G. Bovée, M.D., Ph.D. Department of Pathology Leiden University Medical Center RNA binding DNA binding

More information

Rhabdomyomas and Rhabdomyosarcomas (RMS) David M. Parham, MD Chief of Anatomic Pathology

Rhabdomyomas and Rhabdomyosarcomas (RMS) David M. Parham, MD Chief of Anatomic Pathology Rhabdomyomas and Rhabdomyosarcomas (RMS) David M. Parham, MD Chief of Anatomic Pathology Tumors of skeletal muscle: Rhabdomyomas and rhabdomyosarcomas Embryonal muscle 2 3 4 5 6 7 8 Rhabdomyoma Benign

More information

Lung Tumor Cases: Common Problems and Helpful Hints

Lung Tumor Cases: Common Problems and Helpful Hints Lung Tumor Cases: Common Problems and Helpful Hints Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona Society of Pathologists

More information

Evening Specialty Conference Bone and Soft Tissue Pathology. Diagnostic pitfalls in bone and soft tissue pathology

Evening Specialty Conference Bone and Soft Tissue Pathology. Diagnostic pitfalls in bone and soft tissue pathology Evening Specialty Conference Bone and Soft Tissue Pathology. Case 1 Elizabeth G Demicco, MD, PhD Mount Sinai Hospital, New York Disclosure of Relevant Financial Relationships USCAP requires that all planners

More information

Financial disclosures

Financial disclosures Mesenchymal Neoplasms with Melanocytic Differentiation By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center Geisel

More information

Diplomate of the American Board of Pathology in Anatomic and Clinical Pathology

Diplomate of the American Board of Pathology in Anatomic and Clinical Pathology A 33-year-old male with a left lower leg mass. Contributed by Shaoxiong Chen, MD, PhD Assistant Professor Indiana University School of Medicine/ IU Health Partners Department of Pathology and Laboratory

More information

Recent Advances In Select Round Cell Sarcomas

Recent Advances In Select Round Cell Sarcomas Recent Advances In Select Round Cell Sarcomas Rajiv M. Patel, M.D. Associate Professor of Pathology & Dermatology University of Michigan, Ann Arbor, MI rajivpat@med.umich.edu 1 Translocation Associated

More information

An Overview of Genital Stromal Tumors

An Overview of Genital Stromal Tumors An Overview of Genital Stromal Tumors By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center Geisel School of Medicine

More information

Protocol for the Examination of Biopsy Specimens From Pediatric Patients With Ewing Sarcoma

Protocol for the Examination of Biopsy Specimens From Pediatric Patients With Ewing Sarcoma Protocol for the Examination of Specimens From Pediatric Patients With Ewing Sarcoma Version: EwingSarcoma 4.0.0.0 Protocol Posting Date: February 2019 Accreditation Requirements The use of this protocol

More information

Pathology Mystery and Surprise

Pathology Mystery and Surprise Pathology Mystery and Surprise Tim Smith, MD Director Anatomic Pathology Medical University of South Carolina Disclosures No conflicts to declare Some problem cases Kidney tumor Scalp tumor Bladder tumor

More information

Case 1. Disclosure. Imaging. Clinical history 5/10/2016. USCAP 2016 Annual Meeting Evening Specialty Conference Bone and Soft tissue Pathology

Case 1. Disclosure. Imaging. Clinical history 5/10/2016. USCAP 2016 Annual Meeting Evening Specialty Conference Bone and Soft tissue Pathology Disclosure Dr. Agaram has nothing to disclose Case 1 Narsi Agaram, MBBS USCAP 2016 Annual Meeting Evening Specialty Conference Bone and Soft tissue Pathology Clinical history Imaging 1998 A three month

More information

5/10. Pathology Soft tissue tumors. Farah Bhani. Mohammed Alorjani

5/10. Pathology Soft tissue tumors. Farah Bhani. Mohammed Alorjani 5/10 Pathology Soft tissue tumors Mohammed Alorjani Farah Bhani Slides are included in this sheet. Objectives: Soft tissue tumors 1. Describe soft tissue tumors. 2. Understand the classification of soft

More information

NEW IHC A n t i b o d i e s

NEW IHC A n t i b o d i e s NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology

More information

Keywords solitary fibrous tumor, dedifferentiation, dedifferentiated solitary fibrous tumor, STAT6, GRIA2, cytokeratin, rhabdomyosarcomatous

Keywords solitary fibrous tumor, dedifferentiation, dedifferentiated solitary fibrous tumor, STAT6, GRIA2, cytokeratin, rhabdomyosarcomatous 758452IJSXXX10.1177/1066896918758452International Journal of Surgical PathologyCreytens et al research-article2018 Pitfalls in Pathology Multifocal Cytokeratin Expression in a Dedifferentiated Solitary

More information

Aspen conference on pediatric disease. July through August Bone and Soft Tissue Update. David M. Parham, MD. Rhabdomyoma and rhabdomyosarcoma

Aspen conference on pediatric disease. July through August Bone and Soft Tissue Update. David M. Parham, MD. Rhabdomyoma and rhabdomyosarcoma Aspen conference on pediatric disease July through August 2014 Bone and Soft Tissue Update David M. Parham, MD Rhabdomyoma and rhabdomyosarcoma Embryonic rhabdomyogenesis is a highly conserved process

More information

Technology from Abcam

Technology from Abcam CD2 (EP222) CD2 is one of the earliest T-cell lineage restricted antigens to appear during T-cell differentiation and only rare CD2+ cells can be found in the bone marrow. Anti-CD2 is a pan-t-cell antigen

More information

Diagnostic Value of Immunohistochemistry in Soft Tissue Tumors

Diagnostic Value of Immunohistochemistry in Soft Tissue Tumors Original Article DOI: 10.21276/APALM.1637 Diagnostic Value of Immunohistochemistry in Soft Tissue Tumors Sridevi. V*., Susruthan Muralitharan., and Thanka. J Dept of Pathology, SriMuthukumaran Medical

More information

Spindle Cell Lesions Of The Breast. Emad Rakha Professor of Breast Pathology and Consultant Pathologist

Spindle Cell Lesions Of The Breast. Emad Rakha Professor of Breast Pathology and Consultant Pathologist Spindle Cell Lesions Of The Breast Emad Rakha Professor of Breast Pathology and Consultant Pathologist * SCLs comprise a wide spectrum of diseases, ranging from reactive processes to aggressive malignant

More information

3/27/2017. Disclosure of Relevant Financial Relationships

3/27/2017. Disclosure of Relevant Financial Relationships Ophthalmic Pathology Evening Specialty Conference USCAP 2017 5 th March, 2017 Mukul K. Divatia, MD Assistant Professor Department of Pathology & Genomic Medicine Weill Cornell Medical College Houston Methodist

More information

USCAP COMPANION MEETING INTERNATIONAL SOCIETY OF BONE AND SOFT TISSUE PATHOLOGY DENVER, March 2 nd 2008

USCAP COMPANION MEETING INTERNATIONAL SOCIETY OF BONE AND SOFT TISSUE PATHOLOGY DENVER, March 2 nd 2008 1 USCAP COMPANION MEETING INTERNATIONAL SOCIETY OF BONE AND SOFT TISSUE PATHOLOGY DENVER, March 2 nd 2008 THE EVOLUTION OF SOFT TISSUE TUMOUR TAXONOMY: WHAT STILL NEEDS TO BE DONE? Christopher D.M. Fletcher,

More information

Mesothelioma Pathobasic. Lukas Bubendorf Pathology

Mesothelioma Pathobasic. Lukas Bubendorf Pathology Mesothelioma Pathobasic Lukas Bubendorf Pathology Mechanisms of Asbestos Carcinogenesis in Mesothelioma Asprin High-mobility group protein B1 master switch HMGB1 Initiation/ perpetuation of inflamm. response

More information

ESS: Pathologic Insights

ESS: Pathologic Insights GEIS XVI INTERNATIONAL SYMPOSIUM Seville 4th October 2018 ESS: Pathologic Insights Sílvia Bagué The Royal Marsden Hospital London (United Kingdom) I have no conflicts of interest Endometrial stromal sarcoma

More information

57th Annual HSCP Spring Symposium 4/16/2016

57th Annual HSCP Spring Symposium 4/16/2016 An Unusual Malignant Spindle Cell Lesion to Involve the Breast Erinn Downs-Kelly, D.O. Associate Professor of Pathology University of Utah & ARUP Laboratories No disclosures Case 39 y/o female with no

More information

An Overview of Cutaneous Vascular Neoplasms

An Overview of Cutaneous Vascular Neoplasms An Overview of Cutaneous Vascular Neoplasms By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center Geisel School

More information

* I have no disclosures or any

* I have no disclosures or any Howard Rosenthal, M.D. Associate Professor of Orthopedic Surgery University of Kansas Sarcoma Center I have no disclosures or any conflicts related to the content of this presentation. Objectives 1. Describe

More information

RARE TUMORS OF INFANCY. RAJKUMAR VENKATRAMANI, MD, MS Director, Rare Tumors Program, Texas Children s Hospital

RARE TUMORS OF INFANCY. RAJKUMAR VENKATRAMANI, MD, MS Director, Rare Tumors Program, Texas Children s Hospital RARE TUMORS OF INFANCY RAJKUMAR VENKATRAMANI, MD, MS Director, Rare Tumors Program, Texas Children s Hospital OBJECTIVES Review the epidemiology and clinical presentation of soft tissue sarcomas in infancy.

More information

Fluorescence In Situ Hybridization in the Diagnosis of Soft Tissue Neoplasms: A Review. Munir R. Tanas, MD and John R.

Fluorescence In Situ Hybridization in the Diagnosis of Soft Tissue Neoplasms: A Review. Munir R. Tanas, MD and John R. REVIEW ARTICLE Fluorescence In Situ Hybridization in the Diagnosis of Soft Tissue Neoplasms: A Review Munir R. Tanas, MD and John R. Goldblum, MD Abstract: This paper presents an overview of the role of

More information

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran

More information

Classification (1) Classification (3) Classification (2) Spindle cell lesions. Spindle cell lesions of bladder (Mills et al.

Classification (1) Classification (3) Classification (2) Spindle cell lesions. Spindle cell lesions of bladder (Mills et al. Non-epithelial tumours and nonepithelial tumour-like lesions of the bladder Dr Jonathan H Shanks The Christie NHS Foundation Trust, Manchester, UK Classification (1) Myofibroblastic proliferations and

More information

Contents Part I Introduction 1 General Description 2 Natural History: Importance of Size, Site, Histopathology

Contents Part I Introduction 1 General Description 2 Natural History: Importance of Size, Site, Histopathology Contents Part I Introduction 1 General Description... 3 1.1 Introduction... 3 1.2 Incidence and Prevalence... 5 1.3 Predisposing and Genetic Factors... 8 References... 16 2 Natural History: Importance

More information

Aspen 2014: Cases 1-4. John Hicks Texas Children s Hospital Baylor College of Medicine Houston, Tx. Case 1 History

Aspen 2014: Cases 1-4. John Hicks Texas Children s Hospital Baylor College of Medicine Houston, Tx. Case 1 History Aspen 2014: Cases 1-4 John Hicks Texas Children s Hospital Baylor College of Medicine Houston, Tx Case 1 History 2-month old full-term female presented with respiratory distress for 5 days with stridor.

More information

Case Presentations 17-20

Case Presentations 17-20 Case Presentations 17-20 Case Presentations 17 Case 17 2 year old boy with history of urinary retention and prostate biopsy. After biopsy and chemotherapy, child regains urine flow but the mass does not

More information

Introduction to Musculoskeletal Tumors. James C. Wittig, MD Orthopedic Oncologist Sarcoma Surgeon

Introduction to Musculoskeletal Tumors. James C. Wittig, MD Orthopedic Oncologist Sarcoma Surgeon Introduction to Musculoskeletal Tumors James C. Wittig, MD Orthopedic Oncologist Sarcoma Surgeon www.tumorsurgery.org Definitions Primary Bone / Soft tissue tumors Mesenchymally derived tumors (Mesodermal)

More information

Pathology of Sarcoma ELEANOR CHEN, MD, PHD, ASSISTANT PROFESSOR DEPARTMENT OF PATHOLOGY UNIVERSITY OF WASHINGTON

Pathology of Sarcoma ELEANOR CHEN, MD, PHD, ASSISTANT PROFESSOR DEPARTMENT OF PATHOLOGY UNIVERSITY OF WASHINGTON Pathology of Sarcoma ELEANOR CHEN, MD, PHD, ASSISTANT PROFESSOR DEPARTMENT OF PATHOLOGY UNIVERSITY OF WASHINGTON Presentation outline Background and epidemiology of sarcomas Sarcoma classification Sarcoma

More information

SYLLABUS SWI/SNF-dependent tumors

SYLLABUS SWI/SNF-dependent tumors SYLLABUS SWI/SNF-dependent tumors F Le Loarer, MD, PhD Centre Leon Berard, Department of Pathology, Lyon, FRANCE Since the seminal description in 1999 of recurrent inactivation of SMARCB1- which encodes

More information

The Genetics of Myoepithelial Tumors: salivary glands, soft tissue and bone

The Genetics of Myoepithelial Tumors: salivary glands, soft tissue and bone The Genetics of Myoepithelial Tumors: salivary glands, soft tissue and bone Cristina Antonescu, MD Memorial Sloan-Kettering Cancer Center, New York Nothing to declare Disclosure Spectrum of Myoepithelial

More information

Molecular Genetics of Paediatric Tumours. Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA

Molecular Genetics of Paediatric Tumours. Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA Molecular Genetics of Paediatric Tumours Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA Financial Disclosure NanoString - conference costs for

More information

Cheryl M. Coffin, M.D. Goodpasture Professor of Pathology, Microbiology, and Immunology Vanderbilt University Nashville, TN, USA

Cheryl M. Coffin, M.D. Goodpasture Professor of Pathology, Microbiology, and Immunology Vanderbilt University Nashville, TN, USA Cutaneous Mesenchymal Tumors in Childhood Cheryl M. Coffin, M.D. Goodpasture Professor of Pathology, Microbiology, and Immunology Vanderbilt University Nashville, TN, USA I. Introduction Cutaneous tumors

More information

I sarcomi dei tessuti molli

I sarcomi dei tessuti molli Novità e sequenze terapeutiche nelle neoplasie ginecologiche, melanoma e tumori rari: I sarcomi dei tessuti molli Giacomo G. Baldi Oncologia Medica Sandro Pitigliani Nuovo Ospedale S.Stefano Azienda USL

More information

Journal of Solid Tumors, April 2012, Vol. 2, No. 2

Journal of Solid Tumors, April 2012, Vol. 2, No. 2 ORIGINAL ARTICLE Utility of fluorescence in situ hybridization in subclassifying unclassified high-grade sarcomas: A study of 40 cases using break-apart probes of EWSR1, FOXO1A, SS18 and DDIT3 genes Alfredo

More information

Biopsy Interpretation of Spindle cell proliferations of the Serosa

Biopsy Interpretation of Spindle cell proliferations of the Serosa Biopsy Interpretation of Spindle cell proliferations of the Serosa Richard Attanoos, Cardiff. U.K. Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee)

More information

ACCME/Disclosures ALK FUSION-POSITIVE MESENCHYMAL TUMORS. Tumor types with ALK rearrangements. Anaplastic Lymphoma Kinase. Jason L.

ACCME/Disclosures ALK FUSION-POSITIVE MESENCHYMAL TUMORS. Tumor types with ALK rearrangements. Anaplastic Lymphoma Kinase. Jason L. Companion Meeting of the International Society of Bone and Soft Tissue Pathology The Evolving Concept of Mesenchymal Tumors ALK FUSION-POSITIVE MESENCHYMAL TUMORS Jason L. Hornick, MD, PhD March 13, 2016

More information

Mesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016

Mesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016 Mesothelioma: diagnostic challenges from a pathological perspective Naseema Vorajee August 2016 Naseema.vorajee@nhls.ac.za Pleural diseases (whether neoplastic, reactive or infective) may have similar

More information

What is New in the 2015 WHO Lung Cancer Classification? Zhaolin Xu, MD, FRCPC, FCAP

What is New in the 2015 WHO Lung Cancer Classification? Zhaolin Xu, MD, FRCPC, FCAP What is New in the 2015 WHO Lung Cancer Classification? Zhaolin Xu, MD, FRCPC, FCAP Professor, Dept of Pathology, Dalhousie University, Canada Pulmonary Pathologist and Cytopathologist, QEII HSC Senior

More information

Affiliazione autori0. Riccardo Ricci Journal Club GIPAD, settore GIST Anatomia Patologica, Università Cattolica, Roma

Affiliazione autori0. Riccardo Ricci Journal Club GIPAD, settore GIST Anatomia Patologica, Università Cattolica, Roma GIST Manifesting as a Retroperitoneal Tumor: Clinicopathologic Immunohistochemical, and Molecular Genetic Study of 112 Cases American Journal of Surgical Pathology, 2017, 41:577-585 Miettinen M*; Felisiak-Golabek

More information

Problem 1: Differential of Neuroendocrine Carcinoma 3/23/2017. Disclosure of Relevant Financial Relationships

Problem 1: Differential of Neuroendocrine Carcinoma 3/23/2017. Disclosure of Relevant Financial Relationships Differential of Neuroendocrine Carcinoma Alain C. Borczuk,MD Weill Cornell Medicine Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control

More information

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific Effective January 1, 2018 codes, behaviors and terms are site specific /N 8551/3 Acinar adenocarcinoma (C34. _) Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3

More information

Grading of Bone Tumors

Grading of Bone Tumors Grading of Bone Tumors Joon Hyuk Choi, M.D. Department of Pathology College of Medicine, Yeungnam University Introduction to grading system of bone tumor used at Mayo Clinic WHO Histologic Classification

More information

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific Effective January 1, 2018 codes, behaviors and terms are site specific Status /N 8010/3 Urachal carcinoma (C65.9, C66.9, C67. _, C68._) 8013/3 Combined large cell neuroendocrine carcinoma (C34. _, C37.9)

More information

Shintaro Sugita *, Hiroko Asanuma and Tadashi Hasegawa

Shintaro Sugita *, Hiroko Asanuma and Tadashi Hasegawa Sugita et al. Diagnostic Pathology (2016) 11:37 DOI 10.1186/s13000-016-0486-2 RESEARCH Open Access Diagnostic use of fluorescence in situ hybridization in expert review in a phase 2 study of trabectedin

More information

Mayo Medical Laboratories

Mayo Medical Laboratories Mayo Medical Laboratories Virtual Lectures 2014 MFMER 2016 MFMER slide-1 Virtual Lectures Planning Committee Disclosure Summary As a provider accredited by ACCME, College of Medicine, Mayo Clinic (Mayo

More information

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology Songlin Zhang, MD, PhD LSUHSC-Shreveport I have no Conflict of Interest. FNA on Lymphoproliferative

More information

Part 1. Slides 1-38, Rita Alaggio Soft tissue tumors Trondheim 14. mars 2013

Part 1. Slides 1-38, Rita Alaggio Soft tissue tumors Trondheim 14. mars 2013 Part 1 Slides 1-38, Rita Alaggio Soft tissue tumors Trondheim 14. mars 2013 Pediatric Pathology Soft Tissue Tumors AN UPDATE Rita Alaggio Azienda Ospedaliera Università di Padova Soft Tissue Tumors More

More information

IMMUNOHISTOCHEMISTRY IN THE DIAGNOSIS OF SOFT TISSUE TUMORS

IMMUNOHISTOCHEMISTRY IN THE DIAGNOSIS OF SOFT TISSUE TUMORS IMMUNOHISTOCHEMISTRY IN THE DIAGNOSIS OF SOFT TISSUE TUMORS Nicolas de Saint Aubain Somerhausen Institut Jules Bordet / Hôpital Erasme nicolas.desaintaubain@synet.be ForPath 2005 1 I. Ancillary techniques

More information

Musculoskeletal Sarcomas

Musculoskeletal Sarcomas Musculoskeletal Sarcomas Robert C. Orth, M.D., Ph.D. Edward B. Singleton Department of Pediatric Radiology Texas Children s Hospital Page 0 xxx00.#####.ppt 9/23/2012 9:01:18 AM No disclosures Page 1 xxx00.#####.ppt

More information

Disclosure of Relevant Financial Relationships

Disclosure of Relevant Financial Relationships Neuropathology Evening Specialty Conference Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME activities disclose

More information

2018 ICD-O-3 Updates in Table Format with Annotation for Reference

2018 ICD-O-3 Updates in Table Format with Annotation for Reference Status Histology Description (this may be preferred term or a synonym) Report Comments New term 8010 3 Urachal carcinoma (C65.9, C66.9, C67._, C68._) New term 8013 3 Combined large cell neuroendocrine

More information

Case 2. Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset

Case 2. Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset Case 2 Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset History 24 year old male presented with a 3 day history of right flank pain, sharp in nature Denies fever, chills, hematuria or

More information

Newer soft tissue entities

Newer soft tissue entities Newer soft tissue entities Examples among fibroblastic tumors Turku, May 6, 2010 Markku Miettinen, M.D. AFIP, Washington, DC Fibroblastic neoplasms Solitary fibrous tumor /Hemangiopericytoma Low-grade

More information

4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD

4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as

More information

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,

More information

Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors

Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors & 2014 USCAP, Inc. All rights reserved 0893-3952/14 $32.00 S47 Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors Jason L Hornick Department of Pathology, Brigham

More information

Soft Tissue High Grade Myoepithelial Carcinoma With Round Cell Morphology: Report Of A Newly Described Entity With EWSR1 Gene Rearrangement

Soft Tissue High Grade Myoepithelial Carcinoma With Round Cell Morphology: Report Of A Newly Described Entity With EWSR1 Gene Rearrangement Soft Tissue High Grade Myoepithelial Carcinoma With Round Cell Morphology: Report Of A Newly Described Entity With EWSR1 Gene Rearrangement Abstract M. El-Kabany, R. Al-Abdulghani, A. E. Ali, I. M. Francis,

More information

Dystrophin Is a Tumor Suppressor in Human Cancers with Myogenic Programs

Dystrophin Is a Tumor Suppressor in Human Cancers with Myogenic Programs SUPPLEMENTARY INFORMATION Dystrophin Is a Tumor Suppressor in Human Cancers with Myogenic Programs Yuexiang Wang 1, Adrian Marino-Enriquez 1, Richard R. Bennett 2, Meijun Zhu 1, Yiping Shen 3,4, Grant

More information

Cerebral Parenchymal Lesions: I. Metastatic Neoplasms

Cerebral Parenchymal Lesions: I. Metastatic Neoplasms Chapter 4 Cerebral Parenchymal Lesions: I. Metastatic Neoplasms After one has reasonably ruled out the possibility of a nonneoplastic diagnosis (see Chap. 3), one is left with considering a diagnosis of

More information

A 25 year old female with a palpable mass in the right lower quadrant of her abdomen

A 25 year old female with a palpable mass in the right lower quadrant of her abdomen May 2016 A 25 year old female with a palpable mass in the right lower quadrant of her abdomen Contributed by: Paul Ndekwe, MD, Resident Physician, Indiana University School of Department of Pathology and

More information

Original Articles. Utilization of Fluorescence In Situ Hybridization in the Diagnosis of 230 Mesenchymal Neoplasms. An Institutional Experience

Original Articles. Utilization of Fluorescence In Situ Hybridization in the Diagnosis of 230 Mesenchymal Neoplasms. An Institutional Experience Original Articles Utilization of Fluorescence In Situ Hybridization in the Diagnosis of 230 Mesenchymal Neoplasms An Institutional Experience Munir R. Tanas, MD; Brian P. Rubin, MD, PhD; Raymond R. Tubbs,

More information

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification

More information

number Done by Corrected by Doctor Maha Shomaf

number Done by Corrected by Doctor Maha Shomaf number 16 Done by Waseem Abo-Obeida Corrected by Zeina Assaf Doctor Maha Shomaf MALIGNANT NEOPLASMS The four fundamental features by which benign and malignant tumors can be distinguished are: 1- differentiation

More information

Slide Seminar Spanish Society of Pathology

Slide Seminar Spanish Society of Pathology Slide Seminar Spanish Society of Pathology John R. Goldblum, M.D. Chairman, Department of Anatomic Pathology Cleveland Clinic Professor of Pathology Cleveland Clinic Lerner College of Medicine 1921 Original

More information

HOW MAY THE CLASSIFICATION OF SOFT TISSUE TUMORS EVOLVE?

HOW MAY THE CLASSIFICATION OF SOFT TISSUE TUMORS EVOLVE? Spanish Society of Pathology Zaragoza, May 2011 ARTHUR PURDY STOUT SYMPOSIUM HOW MAY THE CLASSIFICATION OF SOFT TISSUE TUMORS EVOLVE? Christopher D.M. Fletcher, M.D., FRCPath Brigham and Women s Hospital

More information

Notice of Faculty Disclosure

Notice of Faculty Disclosure Mesenchymal Tumors of the Vulva: Old, New, Something(s) Different Napa Valley Conference Pathology Education Partners Inc May 15, 2018 Teri A. Longacre, M.D. longacre@stanford.edu Stanford University,

More information

Role of immunohistochemistry in the differential diagnosis of malignant small round cell tumor: a study of 38 cases

Role of immunohistochemistry in the differential diagnosis of malignant small round cell tumor: a study of 38 cases International Journal of Research in Medical Sciences Patel A et al. Int J Res Med Sci. 2015 Dec;3(12):3833-3839 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20151452

More information

Paediatric small round cell sarcomas an update

Paediatric small round cell sarcomas an update 1 Paediatric small round cell sarcomas an update International Society of Bone and Soft Tissue Pathology meeting, Baltimore, MD March 3, 2013 David M. Parham, MD Oklahoma University Health Science Center

More information

A neoplasm is defined as "an abnormal tissue proliferation, which exceeds that of adjacent normal tissue. This proliferation continues even after

A neoplasm is defined as an abnormal tissue proliferation, which exceeds that of adjacent normal tissue. This proliferation continues even after NEOPLASIA Neoplasia is a very important topic in pathology because neoplasms are both common and serious diseases. A neoplasm literally means a new growth, and this term is used interchangeably with a

More information

Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases

Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases Adrenal cortical carcinoma Inhibin Synap Melan-A Calretinin Vimentin Chromogr CK7 CK20 Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2

More information

2 Berkeley Street, Suite 403, Toronto, Ontario M5A 2W3 Visit us at: Tel: Fax:

2 Berkeley Street, Suite 403, Toronto, Ontario M5A 2W3 Visit us at:  Tel: Fax: E-Path A.I. Engine Knowledge Base Enhancements Version 1.0.0.29 April 1, 2018 The major enhancements in the E-Path Knowledge Base from versions 1.0.0.28 through 1.0.0.29 are as follows: 1. Addition/modification

More information

Molecular pathology/genetics of sarcomas

Molecular pathology/genetics of sarcomas Molecular pathology/genetics of sarcomas Gunhild Mechtersheimer Institute of Pathology, University of Heidelberg Sarkomkonferenz: 17.03.2011 Berlin Characterization of soft tissue sarcomas / STS (~ 1%

More information

Case of the month. Dr Charles Bénière, Institut universitaire de pathologie, Lausanne

Case of the month. Dr Charles Bénière, Institut universitaire de pathologie, Lausanne Case of the month Dr Charles Bénière, Institut universitaire de pathologie, Lausanne Clinical history 39 years old male, smoker (19 pack-year) without any prior medical record nor professional exposure.

More information

Gross appearance of peritoneal cysts. They have a thin, translucent wall and contain a clear fluid.

Gross appearance of peritoneal cysts. They have a thin, translucent wall and contain a clear fluid. Gross appearance of peritoneal cysts. They have a thin, translucent wall and contain a clear fluid. So-called multicystic benign mesothelioma. A, Gross appearance. So-called multicystic benign mesothelioma.

More information

Selected Pseudomalignant Soft Tissue Tumors of the Skin and Subcutis

Selected Pseudomalignant Soft Tissue Tumors of the Skin and Subcutis Selected Pseudomalignant Soft Tissue Tumors of the Skin and Subcutis Andrew L. Folpe, M.D. Professor of Laboratory Medicine and Pathology Mayo Clinic, Rochester, MN folpe.andrew@mayo.edu 2016 MFMER slide-1

More information

Mojca Velikonja Jože Pižem

Mojca Velikonja Jože Pižem Mojca Velikonja Jože Pižem An 81-year old woman presented with an exophytic, wart-like skin lesion on her neck that she had observed for one year. Cryotherapy had been applied twice, but proved unsuccessful.

More information

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture Neoplasia part I By Dr. Mohsen Dashti Clinical Medicine & Pathology 316 2 nd Lecture Lecture outline Review of structure & function. Basic definitions. Classification of neoplasms. Morphologic features.

More information

Conceptual Evolution of Soft Tissue Tumors Classification

Conceptual Evolution of Soft Tissue Tumors Classification Conceptual Evolution of Soft Tissue Tumors Classification Angelo P. Dei Tos M.D. Departments of Pathology & Oncology Treviso, Italy How WHO classification was reshaped Pathologists and Cytogeneticists

More information

Update on Cutaneous Mesenchymal Tumors. Thomas Brenn

Update on Cutaneous Mesenchymal Tumors. Thomas Brenn Update on Cutaneous Mesenchymal Tumors Thomas Brenn Cutaneous Mesenchymal Tumours Wide morphological and biological spectrum Myofibroblastic, smooth muscle, neural, vascular, apidocytic, undifferentiated;

More information

LOOK-ALIKES IN SPINDLE AND EPITHELIOID TUMORS: Immunohistochemistry. Cytogenetics Flow cytometry Molecular diagnostics

LOOK-ALIKES IN SPINDLE AND EPITHELIOID TUMORS: Immunohistochemistry. Cytogenetics Flow cytometry Molecular diagnostics LOOK-ALIKES IN SPINDLE AND EPITHELIOID TUMORS: Ultrastructural value and pitfalls in diagnosis Guillermo A Herrera Department of Pathology and Translational Pathobiology Louisiana State University Health

More information

GUT-C 11/30/2017. Debasmita Das, M.D. PGY-1 Danbury Hospital

GUT-C 11/30/2017. Debasmita Das, M.D. PGY-1 Danbury Hospital GUT-C 11/30/2017 Debasmita Das, M.D. PGY-1 Danbury Hospital CLINICAL SUMMARY 8/2017 59 year old female Presented to the ED with 1 month history of general malaise, fever and weight loss PMH: Significant

More information